Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Hawkes EA"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-14 z 14
    Tytuł:
    Treatment of metastatic colorectal cancer: focus on panitumumab
    Autorzy:
    Tay RY
    Wong R
    Hawkes EA
    Pokaż więcej
    Temat:
    Neoplasms. Tumors. Oncology. Including cancer and carcinogens
    RC254-282
    Źródło:
    Cancer Management and Research, Vol 2015, Iss default, Pp 189-198 (2015)
    Opis pliku:
    electronic resource
    Relacje:
    http://www.dovepress.com/treatment-of-metastatic-colorectal-cancer-focus-on-panitumumab-peer-reviewed-article-CMAR; https://doaj.org/toc/1179-1322
    Dostęp URL:
    https://doaj.org/article/b6d323f0b9434defabbf0750cab0b2d5  Link otwiera się w nowym oknie
    Czasopismo naukowe
    Szczegóły
    Tytuł:
    Prognostic Markers within the Tumour Microenvironment in Classical Hodgkin Lymphoma.
    Autorzy:
    Martynchyk A; Olivia Newton-John Cancer Research & Wellness Centre, Austin Health, 145 Studley Rd., Heidelberg, VIC 3084, Australia.
    Chowdhury R; Princess Alexandra Hospital, 199 Ipswich Rd., Woolloongabba, QLD 4102, Australia.; Frazer Institute, University of Queensland, St. Lucia, QLD 4072, Australia.
    Hawkes EA; Olivia Newton-John Cancer Research & Wellness Centre, Austin Health, 145 Studley Rd., Heidelberg, VIC 3084, Australia.; School of Public Health & Preventive Medicine, Monash University, 553 St Kilda Rd., Melbourne, VIC 3004, Australia.
    Keane C; Princess Alexandra Hospital, 199 Ipswich Rd., Woolloongabba, QLD 4102, Australia.; Frazer Institute, University of Queensland, St. Lucia, QLD 4072, Australia.
    Pokaż więcej
    Źródło:
    Cancers [Cancers (Basel)] 2023 Oct 30; Vol. 15 (21). Date of Electronic Publication: 2023 Oct 30.
    Typ publikacji:
    Journal Article; Review
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Clinical characteristics of Australian treatment-naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry.
    Autorzy:
    Nguyen J; Eastern Health, Melbourne, Victoria, Australia.
    Wellard C; Monash University School of Public Health & Preventive Medicine, Melbourne, Victoria, Australia.
    Chung E; Monash University School of Public Health & Preventive Medicine, Melbourne, Victoria, Australia.
    Cheah CY; Sir Charles Gairdner Hospital and Medical School, University of Western Australia, Western Australia, Australia.
    Dickinson M; Peter MacCallum Cancer Centre; Royal Melbourne Hospital, and the Sir Peter MacCallum Department of Oncology at the University of Melbourne, Melbourne, Victoria, Australia.
    Doo NW; Concord Repatriation General Hospital; Concord Clinical School, University of Sydney, Concord, New South Wales, Australia.
    Keane C; Princess Alexandra Hospital, Queensland, Australia.
    Talaulikar D; Canberra Health Services, The Australian National University, Australian Capital Territory, Australia.
    Berkahn L; Auckland City Hospital, Auckland, New Zealand.
    Morgan S; Alfred Health, Melbourne, Victoria, Australia.
    Hamad N; St Vincent's Hospital Sydney, Sydney, New South Wales, Australia.
    Cochrane T; Gold Coast University Hospital, Griffith University, Southport, Queensland, Australia.
    Johnston AM; Royal Hobart Hospital, Tasmania, Australia.
    Forsyth C; Gosford Hospital, New South Wales, Australia.
    Opat S; Monash Health, Victoria, Australia.
    Barraclough A; Fiona Stanley Hospital, Western Australia, Australia.
    Mutsando H; Toowoomba Hospital, Queensland, Australia.
    Ratnasingam S; University Hospital Geelong, Victoria, Australia.
    Giri P; Royal Adelaide Hospital, South Australia, Australia.
    Wood EM; Monash University School of Public Health & Preventive Medicine, Melbourne, Victoria, Australia.
    McQuilten ZK; Monash University School of Public Health & Preventive Medicine, Melbourne, Victoria, Australia.
    Hawkes EA; Monash University School of Public Health & Preventive Medicine, Melbourne, Victoria, Australia.; Olivia Newton John Cancer Research Institute at Austin Health, Victoria, Australia.
    Pokaż więcej
    Corporate Authors:
    Lymphoma and Related Diseases Registry investigators
    Źródło:
    European journal of haematology [Eur J Haematol] 2023 Apr; Vol. 110 (4), pp. 386-395. Date of Electronic Publication: 2022 Dec 28.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Hodgkin Disease*
    Humans ; Bleomycin/therapeutic use ; Doxorubicin/therapeutic use ; Vinblastine/therapeutic use ; Dacarbazine/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Australia ; Registries ; Neoplasm Staging
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry.
    Autorzy:
    Baggio D; Olivia Newton John Cancer Research and Wellness Centre, Austin Health, Heidelberg, Australia.
    Wellard C; School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
    Chung E; School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
    Talaulikar D; Canberra Health, Australian Capital Territory, Canberra, Australia.
    Keane C; Princess Alexandra Hospital, Woolloongabba, Australia.
    Opat S; School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.; Monash Health, Clayton, Australia.
    Giri P; Royal Adelaide Hospital, Adelaide, Australia.
    Minson A; Peter MacCallum Cancer Centre, Melbourne, Australia.; The Royal Melbourne Hospital, Parkville, Australia.
    Cheah CY; Sir Charles Gairdner Hospital, Nedlands, Australia.
    Armytage T; Gosford Hospital, Gosford, Australia.
    Lee D; Eastern Health, Box Hill, Australia.
    Chong G; Ballarat Regional Integrated Cancer Centre, Ballarat, Australia.
    Johnston A; Royal Hobart Hospital, Hobart, Australia.
    Cochrane T; Gold Coast University Hospital, Southport, Australia.
    Waters N; School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
    Hamad N; St Vincent's Health, Darlinghurst, Australia.
    Wood EM; School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
    Hawkes EA; Olivia Newton John Cancer Research and Wellness Centre, Austin Health, Heidelberg, Australia.; School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2023 Mar; Vol. 64 (3), pp. 621-627. Date of Electronic Publication: 2022 Dec 21.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Lymphoma, Mantle-Cell*/pathology
    Adenine/*analogs & derivatives
    Adult ; Humans ; Australia/epidemiology ; Piperidines/therapeutic use ; Registries
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Toxicity associated with high-dose intravenous methotrexate for hematological malignancies.
    Autorzy:
    Wight J; Austin Health, Heidelberg, Australia.; Olivia Newton John Cancer Research Institute, Victoria, Australia.; The University of Melbourne, Melbourne, Australia.; Townsville University Hospital, Townsville, Australia.
    Ku M; The University of Melbourne, Melbourne, Australia.; St Vincent's Hospital, Melbourne, Australia.
    Garwood M; The University of Melbourne, Melbourne, Australia.
    Carradice D; Western Health, Melbourne, Australia.
    Lasica M; Box Hill Hospital, Melbourne, Australia.
    Keamy L; The University of Melbourne, Melbourne, Australia.; Western Health, Melbourne, Australia.
    Hawkes EA; Austin Health, Heidelberg, Australia.; Olivia Newton John Cancer Research Institute, Victoria, Australia.; The University of Melbourne, Melbourne, Australia.; Monash University, Melbourne, Australia.
    Grigg A; Austin Health, Heidelberg, Australia.; The University of Melbourne, Melbourne, Australia.
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2022 Oct; Vol. 63 (10), pp. 2375-2382. Date of Electronic Publication: 2022 May 16.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Drug-Related Side Effects and Adverse Reactions*
    Hematologic Neoplasms*/drug therapy
    Renal Insufficiency*
    Australia/epidemiology ; Humans ; Kidney ; Methotrexate/therapeutic use ; Retrospective Studies
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    A consensus statement on the use of biosimilar medicines in hematology in Australia.
    Autorzy:
    Gregory GP; Monash Haematology, Monash Health, Clayton, Victoria, Australia.; School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.
    Carrington C; Department of Pharmacy, Princess Alexandra Hospital, Brisbane, Queensland, Australia.; School of Pharmacy, University of Queensland, Brisbane, Queensland, Australia.
    Cheah CY; Sir Charles Gairdner Hospital and Pathwest Laboratory Medicine WA, Nedlands, Western Australia, Australia.; Medical School of Pathology and Laboratory Medicine, University of Western Australia, Crawley, Western Australia, Australia.
    Hawkes EA; Olivia Newton-John Cancer Research & Wellness Centre, Austin Health, Melbourne, Victoria, Australia.; Eastern Health, Melbourne, Victoria, Australia.
    Irving IM; The Wesley Hospital, Auchenflower, Queensland, Australia.; Icon Group, Brisbane, Queensland, Australia.
    Siderov J; Department of Pharmacy, Austin Health, Melbourne, Victoria, Australia.
    Opat S; Monash Haematology, Monash Health, Clayton, Victoria, Australia.; School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.; Clinical Haematology, Alfred Health, Melbourne, Victoria, Australia.
    Pokaż więcej
    Źródło:
    Asia-Pacific journal of clinical oncology [Asia Pac J Clin Oncol] 2020 Aug; Vol. 16 (4), pp. 211-221. Date of Electronic Publication: 2020 Apr 14.
    Typ publikacji:
    Journal Article; Review
    MeSH Terms:
    Biosimilar Pharmaceuticals/*therapeutic use
    Hematology/*methods
    Australia ; Biosimilar Pharmaceuticals/pharmacology ; Humans
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    An abscopal effect may augment PD-1 inhibition in refractory classical Hodgkin lymphoma.
    Autorzy:
    Wight JC; a Department of Haematology , Olivia Newton John Cancer and Wellness Centre, Austin Health , Heidelberg , Australia.
    Hawkes EA; a Department of Haematology , Olivia Newton John Cancer and Wellness Centre, Austin Health , Heidelberg , Australia.; b Faculty of Health Sciences , Olivia Newton John Cancer Research Institute, La Trobe University , Heidelberg , Australia.; c Faculty of Health Sciences , Monash University , Melbourne , Australia.; d Department of Oncology , Eastern Health , Box Hill , Australia.
    Berlangieri SU; a Department of Haematology , Olivia Newton John Cancer and Wellness Centre, Austin Health , Heidelberg , Australia.
    Khor R; a Department of Haematology , Olivia Newton John Cancer and Wellness Centre, Austin Health , Heidelberg , Australia.; e Sir Peter MacCallum Department of Oncology , University of Melbourne , Melbourne , Australia.; f Faculty of Health Sciences , University of Melbourne , Melbourne , Australia.
    Grigg AP; a Department of Haematology , Olivia Newton John Cancer and Wellness Centre, Austin Health , Heidelberg , Australia.; f Faculty of Health Sciences , University of Melbourne , Melbourne , Australia.
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2018 Nov; Vol. 59 (11), pp. 2749-2751. Date of Electronic Publication: 2018 Mar 23.
    Typ publikacji:
    Case Reports; Letter
    MeSH Terms:
    Radiotherapy Dosage*
    Hodgkin Disease/*therapy
    Nivolumab/*therapeutic use
    Programmed Cell Death 1 Receptor/*antagonists & inhibitors
    Chemoradiotherapy ; Hodgkin Disease/pathology ; Humans ; Male ; Nivolumab/metabolism ; Programmed Cell Death 1 Receptor/metabolism ; Treatment Outcome ; Young Adult
    Raport
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital.
    Autorzy:
    Gleeson M; a The Royal Marsden Hospital, London and Surrey , UK.
    Peckitt C; a The Royal Marsden Hospital, London and Surrey , UK.
    Cunningham D; a The Royal Marsden Hospital, London and Surrey , UK.
    Gibb A; b The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester , UK.
    Hawkes EA; c Department of Oncology and Clinical Haematology , Austin Health , Heidelberg , Australia.; d Eastern Health , Melbourne , Australia.
    Back M; b The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester , UK.
    Yasar B; b The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester , UK.
    Foley K; b The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester , UK.
    Lee R; b The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester , UK.
    Dash J; b The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester , UK.
    Johnson H; b The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester , UK.
    O'Hara C; b The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester , UK.
    Wotherspoon A; a The Royal Marsden Hospital, London and Surrey , UK.
    Attygalle A; a The Royal Marsden Hospital, London and Surrey , UK.
    Menasce L; b The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester , UK.
    Shenjere P; b The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester , UK.
    Potter M; a The Royal Marsden Hospital, London and Surrey , UK.
    Ethell ME; a The Royal Marsden Hospital, London and Surrey , UK.
    Dearden C; a The Royal Marsden Hospital, London and Surrey , UK.
    Radford J; b The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester , UK.
    Chau I; a The Royal Marsden Hospital, London and Surrey , UK.
    Linton K; b The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester , UK.
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2018 Jul; Vol. 59 (7), pp. 1586-1595. Date of Electronic Publication: 2017 Nov 09.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Lymphoma, T-Cell, Peripheral/*drug therapy
    Lymphoma, T-Cell, Peripheral/*mortality
    Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Biomarkers ; Combined Modality Therapy ; Consolidation Chemotherapy ; Female ; Follow-Up Studies ; Hematopoietic Stem Cell Transplantation/adverse effects ; Hematopoietic Stem Cell Transplantation/methods ; Humans ; Induction Chemotherapy ; Lymphoma, T-Cell, Peripheral/diagnosis ; Male ; Middle Aged ; Neoplasm Metastasis ; Neoplasm Staging ; Prognosis ; Recurrence ; Survival Analysis ; Treatment Outcome ; United Kingdom ; Young Adult
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013.
    Autorzy:
    Gleeson M; a The Royal Marsden Hospital, London and Surrey , United Kingdom.
    Hawkes EA; b Department of Oncology and Clinical Haematology , Austin Health , Heidelberg , Melbourne , Australia.; c Eastern Health , Melbourne , Australia.
    Peckitt C; a The Royal Marsden Hospital, London and Surrey , United Kingdom.
    Wotherspoon A; a The Royal Marsden Hospital, London and Surrey , United Kingdom.
    Attygalle A; a The Royal Marsden Hospital, London and Surrey , United Kingdom.
    Sharma B; a The Royal Marsden Hospital, London and Surrey , United Kingdom.
    Du Y; a The Royal Marsden Hospital, London and Surrey , United Kingdom.
    Ethell M; a The Royal Marsden Hospital, London and Surrey , United Kingdom.
    Potter M; a The Royal Marsden Hospital, London and Surrey , United Kingdom.
    Dearden C; a The Royal Marsden Hospital, London and Surrey , United Kingdom.
    Horwich A; a The Royal Marsden Hospital, London and Surrey , United Kingdom.
    Chau I; a The Royal Marsden Hospital, London and Surrey , United Kingdom.
    Cunningham D; a The Royal Marsden Hospital, London and Surrey , United Kingdom.
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2017 Aug; Vol. 58 (8), pp. 1805-1813. Date of Electronic Publication: 2016 Dec 08.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Antineoplastic Agents, Immunological/*therapeutic use
    Lymphoma, Follicular/*drug therapy
    Lymphoma, Follicular/*pathology
    Rituximab/*therapeutic use
    Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Combined Modality Therapy ; Female ; Hematopoietic Stem Cell Transplantation ; Humans ; Lymphoma, Follicular/mortality ; Lymphoma, Large B-Cell, Diffuse/drug therapy ; Lymphoma, Large B-Cell, Diffuse/mortality ; Lymphoma, Large B-Cell, Diffuse/pathology ; Maintenance Chemotherapy ; Male ; Middle Aged ; Neoplasm Grading ; Neoplasm Staging ; Remission Induction ; Rituximab/administration & dosage ; Rituximab/adverse effects ; Survival Analysis ; Treatment Outcome
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Efficacy and toxicity of PACEBOM chemotherapy in relapsed/refractory aggressive lymphoma in the rituximab era.
    Autorzy:
    Tamjid B; Oncology and Haematology Department, Box Hill Hospital, Melbourne, Victoria, Australia.; Department of Medical Oncology & Clinical Haematology, Olivia Newton John Cancer Research Institute, Austin Hospital, Melbourne, Victoria, Australia.
    Mckendrick J; Oncology and Haematology Department, Box Hill Hospital, Melbourne, Victoria, Australia.
    Schwarer A; Oncology and Haematology Department, Box Hill Hospital, Melbourne, Victoria, Australia.; Department of Medical Oncology & Clinical Haematology, Olivia Newton John Cancer Research Institute, Austin Hospital, Melbourne, Victoria, Australia.
    Doig R; Oncology and Haematology Department, Box Hill Hospital, Melbourne, Victoria, Australia.
    James P; Oncology and Haematology Department, Box Hill Hospital, Melbourne, Victoria, Australia.
    Hosking P; Pathology Department, Box Hill Hospital, Melbourne, Victoria, Australia.
    Hawkes EA; Oncology and Haematology Department, Box Hill Hospital, Melbourne, Victoria, Australia.; Department of Medical Oncology & Clinical Haematology, Olivia Newton John Cancer Research Institute, Austin Hospital, Melbourne, Victoria, Australia.; Monash University, Melbourne, Victoria, Australia.
    Pokaż więcej
    Źródło:
    Asia-Pacific journal of clinical oncology [Asia Pac J Clin Oncol] 2017 Jun; Vol. 13 (3), pp. 226-233. Date of Electronic Publication: 2016 Dec 22.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Antineoplastic Agents, Immunological/*therapeutic use
    Lymphoma/*drug therapy
    Neoplasm Recurrence, Local/*drug therapy
    Rituximab/*therapeutic use
    Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/pharmacology ; Female ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Rituximab/administration & dosage ; Rituximab/pharmacology
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R-GEM-P) is an effective regimen in relapsed diffuse large B-cell lymphoma.
    Autorzy:
    Barton S; The Royal Marsden NHS Foundation Trust, London, Surrey, UK.
    Hawkes EA
    Cunningham D
    Peckitt C
    Chua S
    Wotherspoon A
    Attygalle A
    Horwich A
    Potter M
    Ethell M
    Dearden C
    Gleeson M
    Chau I
    Pokaż więcej
    Źródło:
    European journal of haematology [Eur J Haematol] 2015 Mar; Vol. 94 (3), pp. 219-26. Date of Electronic Publication: 2014 Aug 18.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Antineoplastic Combined Chemotherapy Protocols*
    Lymphoma, Large B-Cell, Diffuse/*drug therapy
    Salvage Therapy/*methods
    Adult ; Aged ; Antibodies, Monoclonal, Murine-Derived/administration & dosage ; Antibodies, Monoclonal, Murine-Derived/adverse effects ; Carboplatin/administration & dosage ; Carboplatin/adverse effects ; Cisplatin/administration & dosage ; Cisplatin/adverse effects ; Deoxycytidine/administration & dosage ; Deoxycytidine/adverse effects ; Deoxycytidine/analogs & derivatives ; Drug Administration Schedule ; Drug Substitution ; Female ; Follow-Up Studies ; Humans ; Lymphoma, Large B-Cell, Diffuse/mortality ; Lymphoma, Large B-Cell, Diffuse/pathology ; Male ; Methylprednisolone/administration & dosage ; Methylprednisolone/adverse effects ; Middle Aged ; Neutropenia/chemically induced ; Neutropenia/pathology ; Recurrence ; Retrospective Studies ; Rituximab ; Survival Analysis ; Thrombocytopenia/chemically induced ; Thrombocytopenia/pathology ; Treatment Outcome ; Gemcitabine
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Diagnosis and management of rare gastrointestinal lymphomas.
    Autorzy:
    Hawkes EA; Royal Marsden Hospital, London and Surrey, UK.
    Wotherspoon A
    Cunningham D
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2012 Dec; Vol. 53 (12), pp. 2341-50. Date of Electronic Publication: 2012 Jun 21.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't; Review
    MeSH Terms:
    Gastrointestinal Neoplasms/*diagnosis
    Gastrointestinal Neoplasms/*therapy
    Lymphoma/*diagnosis
    Lymphoma/*therapy
    Enteropathy-Associated T-Cell Lymphoma/diagnosis ; Enteropathy-Associated T-Cell Lymphoma/therapy ; Humans ; Lymphoma, Extranodal NK-T-Cell/diagnosis ; Lymphoma, Extranodal NK-T-Cell/therapy ; Lymphoma, Follicular/diagnosis ; Lymphoma, Follicular/therapy ; Lymphoma, Mantle-Cell/diagnosis ; Lymphoma, Mantle-Cell/therapy ; Prognosis
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Peri-operative chemotherapy in the management of resectable colorectal cancer pulmonary metastases.
    Autorzy:
    Hawkes EA; Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, UK SM2 5PT.
    Ladas G
    Cunningham D
    Nicholson AG
    Wassilew K
    Barbachano Y
    Ratnayake G
    Rao S
    Chau I
    Pokaż więcej
    Źródło:
    BMC cancer [BMC Cancer] 2012 Aug 01; Vol. 12, pp. 326. Date of Electronic Publication: 2012 Aug 01.
    Typ publikacji:
    Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Adenocarcinoma/*drug therapy
    Adenocarcinoma/*secondary
    Colorectal Neoplasms/*drug therapy
    Colorectal Neoplasms/*pathology
    Lung Neoplasms/*drug therapy
    Lung Neoplasms/*secondary
    Adenocarcinoma/mortality ; Adult ; Aged ; Antineoplastic Agents/therapeutic use ; Colorectal Neoplasms/mortality ; Female ; Humans ; Kaplan-Meier Estimate ; Lung Neoplasms/surgery ; Male ; Metastasectomy ; Middle Aged ; Neoadjuvant Therapy ; Pneumonectomy ; Proportional Hazards Models
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    The unique entity of nodular lymphocyte-predominant Hodgkin lymphoma: current approaches to diagnosis and management.
    Autorzy:
    Hawkes EA; Royal Marsden Hospital, London & Surrey, UK.
    Wotherspoon A
    Cunningham D
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2012 Mar; Vol. 53 (3), pp. 354-61. Date of Electronic Publication: 2011 Sep 19.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't; Review
    MeSH Terms:
    Hodgkin Disease/*pathology
    Antibodies, Monoclonal, Murine-Derived/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bleomycin/administration & dosage ; Clinical Trials as Topic ; Dacarbazine/administration & dosage ; Doxorubicin/administration & dosage ; Histiocytes/pathology ; Hodgkin Disease/classification ; Hodgkin Disease/diagnosis ; Hodgkin Disease/epidemiology ; Hodgkin Disease/therapy ; Humans ; Immunophenotyping ; Lymph Node Excision ; Lymphatic Irradiation/methods ; Lymphocytes/pathology ; Prognosis ; Recurrence ; Rituximab ; Salvage Therapy ; Vinblastine/administration & dosage
    SCR Protocol:
    ABVD protocol
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
      Wyświetlanie 1-14 z 14

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies